Drug Delivery Research Laboratory

Sāgar, India

Drug Delivery Research Laboratory

Sāgar, India
SEARCH FILTERS
Time filter
Source Type

Gupta M.,Drug Delivery Research Laboratory | Agrawal U.,Drug Delivery Research Laboratory | Vyas S.P.,Drug Delivery Research Laboratory
Expert Opinion on Drug Delivery | Year: 2012

Introduction: Skin disorders will continue to cause complications in patients. At present, there is an expansion of research into dermatologic treatment due to a critical need for new treatment options to treat skin diseases. Areas covered: The skin itself provides a natural barrier against particle penetration for topical delivery. However, it also offers a potential approach for the delivery of therapeutics, especially in diseased skin and via the openings of hair follicles. Recent innovation might be achieved in the field of dermatological treatment with improvement in the dermal localization of bioactives into the affected skin region, via novel nanocarriers that deliver the drugs directly to the target cells. After application, these nanocarriers can penetrate through the stratum corneum into viable skin and accumulate at the target site. However, noteworthy uptake does occur after damage and in certain diseased skin. Expert opinion: Skin-targeted topical delivery by means of nanosystems, in order to produce sustained release and maintain a localized effect, will result in an effective treatment of various life-threatening dermatological conditions. In addition, research continues into the interactions between novel particles, skin and skin lipid, and the influence of particle composition on drug distribution within the skin strata. © Informa UK, Ltd.


Gupta S.,Nanomedicine Research Center | Pal A.,Nanomedicine Research Center | Vyas S.P.,Drug Delivery Research Laboratory
Expert Opinion on Drug Delivery | Year: 2010

Importance of the field: Visceral leishmaniasis (VL) is the most overwhelming type of leishmaniasis associated with the poverty of developing countries and usually mortal if untreated. Most of the conventionally used dosage forms offer us the shortcomings of toxic side effects and emergence of drug resistance. Several efforts have been made to overcome the barriers involved in the treatment of VL. Colloidal carriers extensively represent the drug delivery systems (DDSs) for intracellular localization of antileishmanial compounds in macrophage-rich organs such as liver, spleen and bone marrow. These DDSs offer superior therapeutic efficacy over the conventional treatment in terms of site-specific drug delivery with reduced side effects. However, after 35 years of research in the field, AmBisome® (Amphotericin B liposome for injection, Astellas Pharma US, Inc.) is the only DDS used against the VL. Areas covered in this review: A literature search was performed (for drugs and DDSs against VL) on PubMed and through Google. What the reader will gain: This review aims to describe the pathophysiology of VL and its current conventional treatment with special reference to DDSs designed against VL. Take home message: On reviewing the conventional drugs and DDSs developed against VL, it is concluded that advances in the field of targeted drug delivery can result in more efficient strategies for the therapy of VL. © 2010 Informa UK Ltd.


Paliwal S.R.,Guru Ghasidas University | Paliwal R.,Columbia Institute of Pharmacy | Vyas S.P.,Drug Delivery Research Laboratory
Drug Delivery | Year: 2015

The pH-sensitive liposomes have been extensively used as an alternative to conventional liposomes in effective intracellular delivery of therapeutics/antigen/DNA/diagnostics to various compartments of the target cell. Such liposomes are destabilized under acidic conditions of the endocytotic pathway as they usually contain pH-sensitive lipid components. Therefore, the encapsulated content is delivered into the intracellular bio-environment through destabilization or its fusion with the endosomal membrane. The therapeutic efficacy of pH-sensitive liposomes enables them as biomaterial with commercial utility especially in cancer treatment. In addition, targeting ligands including antibodies can be anchored on the surface of pH-sensitive liposomes to target specific cell surface receptors/antigen present on tumor cells. These vesicles have also been widely explored for antigen delivery and serve as immunological adjuvant to enhance the immune response to antigens. The present review deals with recent research updates on application of pH-sensitive liposomes in chemotherapy/diagnostics/antigen/gene delivery etc. © 2014 Informa Healthcare USA, Inc. All rights reserved: reproduction in whole or part not permitted.


Sharma R.,Drug Delivery Research Laboratory | Agrawal U.,Drug Delivery Research Laboratory | Mody N.,Drug Delivery Research Laboratory | Vyas S.P.,Drug Delivery Research Laboratory
Biotechnology Advances | Year: 2015

Mucosal sites serve as the main portal for the entry of pathogens and thus immunization through mucosal routes can greatly improve the immunity. Researchers are continuously exploring the vaccination strategies to engender protective mucosal immune responses. Unearthing of mucosal adjuvants, that are safe and effective, is enhancing the magnitude and quality of the protective immune response. Use of nanotechnology based polymeric nanocarrier systems which encapsulate vaccine components for protection of sensitive payload, incorporate mucosal adjuvants to maximize the immune responses and target the mucosal immune system is a key strategy to improve the effectiveness of mucosal vaccines. These advances promise to accelerate the development and testing of new mucosal vaccines against many human diseases. This review focuses on the need for the development of nanocarrier based mucosal vaccines with emphases on the polymeric nanoparticles, their clinical status and future perspectives. This review focuses on the need and new insights for the development of nanoarchitecture governed mucosal vaccination with emphases on the various polymeric nanoparticles, their clinical status and future perspectives. © 2014 Elsevier Inc.


Agrawal U.,Drug Delivery Research Laboratory | Sharma R.,Drug Delivery Research Laboratory | Gupta M.,Drug Delivery Research Laboratory | Vyas S.P.,Drug Delivery Research Laboratory
Drug Discovery Today | Year: 2014

The oral route for drug delivery is regarded as the optimal route for achieving therapeutic benefits owing to increased patient compliance. Despite phenomenal advances in injectable, transdermal, nasal and other routes of administration, the reality is that oral drug delivery remains well ahead of the pack as the preferred delivery route. Nanocarriers can overcome the major challenges associated with this route of administration: mainly poor solubility, stability and biocompatibility of drugs. This review focuses on the potential of various polymeric drug delivery systems in oral administration, their pharmacokinetics, in vitro and in vivo models, toxicity and regulatory aspects. © 2014 Elsevier Ltd. All rights reserved.


Gupta M.,Drug Delivery Research Laboratory | Vyas S.P.,Drug Delivery Research Laboratory
Chemistry and Physics of Lipids | Year: 2012

The nanoparticulate carrier systems as solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) have gained interest for the topical treatment of skin associated fungal infection as they facilitate the skin penetration of loaded drugs. Therefore in this study, SLNs and NLCs loaded fluconazole (FLZ) were prepared by solvent diffusion method in an aqueous system and characterized for different parameters. In addition, antifungal activity was carried out on experimentally induced cutaneous candidiasis in immunosuppressed albino rats. The results showed that SLNs and NLCs represent the respective mean particle sizes of approx. 178 and 134 nm with encapsulation efficiency of 75.7 ± 4.94% and 81.4 ± 3.89%, respectively. The skin-retention studies of FLZ from in vitro and in vivo experiments revealed significantly higher accumulation of drug in the case of NLCs formulation. The in vivo cumulative amount of FLZ retention from NLCs was more than 5-fold that of the plain solution, while it was 3.3-fold more in the case of an equivalent-dose application in the form of SLNs at 12 h after administration. The antifungal study also confirmed the maximum therapeutic efficacy of NLCs, as the lowest number of cfu/ml was recorded. It can be concluded from this study that NLCs provide a good skin targeting effect and may be a promising carrier for topical delivery of FLZ offering the sustained release and maintain the localized effect, resulting in an effective treatment of a life-threatening cutaneous fungal infection. © 2012 Elsevier Ireland Ltd.


Gupta M.,Drug Delivery Research Laboratory | Agrawal G.P.,Drug Delivery Research Laboratory | Vyas S.P.,Drug Delivery Research Laboratory
Current Molecular Medicine | Year: 2013

Inspite of demanding research that has been undertaken for cancer treatment, cancer is a major cause of mortality. Available conventional treatment options of solid tumor are associated with serious side effects. Nanomedicines mediated fascinating approach may be effectively utilized for efficient tumor targeting by avoiding all the problems associated with conventional chemotherapy. Polymeric nanomedicines such as polymer micelles, polymeric nanoparticles, polymersomes and polymer conjugates currently developed for solid tumor treatment have proved to be efficacious cancer therapeutics. These polymeric nanostructures are able to reach tumor tissue or angiogenic endothelial cells either passively or actively. To date, more advancement in the tumor targeting field includes stimuli sensitive polymeric nanocarriers that pass through the intracellular delivery barriers and release the bioactives in response to the microenvironmental trigger of tumor cell. This review discusses the molecular aspects of solid tumor pathophysiology and its dramatic impact on research for innovative and novel therapeutic approaches linked with tumor-targeting polymeric nanomedicines. © 2013 Bentham Science Publishers.


Paliwal R.,Drug Delivery Research Laboratory | Rai S.,Drug Delivery Research Laboratory | Vyas S.P.,Drug Delivery Research Laboratory
Journal of Biomedical Nanotechnology | Year: 2011

The objective of the study was to develop lipid drug conjugate nanoparticles (LDC-NPs) of anticancer drug methotrexate (MTX) for oral delivery that faces problems of low and variable bioavailability. The MTX loaded LDC-NPs significantly enhanced bioavailability and reduced MTX associated gastrointestinal toxicity even in higher doses recommended for anticancer therapy. Copyright © 2011 American Scientific Publishers All rights reserved.


Rai S.,Drug Delivery Research Laboratory | Paliwal R.,Drug Delivery Research Laboratory | Vyas S.P.,Drug Delivery Research Laboratory
Journal of Biomedical Nanotechnology | Year: 2011

The encapsulation of anticancer agent in carrier system protects healthy tissues from its cytotoxic effects. In the present study estrogen receptor targeted liposomes encapsulating doxorubicin was designed to enhance the efficiency of delivery of doxorubicin to its destination site. The liposomal formulations showed change in the biodistribution profile. Targeted formulation accumulates more in breast and uterine tissues. ER-targeted formulation of antineoplastic agents could be potentially useful for treatment of ER positive tumors such as breast and uterus. Copyright © 2011 American Scientific Publishers All rights reserved.


Gupta M.,Drug Delivery Research Laboratory
Pharmaceutical development and technology | Year: 2013

Dermal delivery of fluconazole (FLZ) is still a major limitation due to problems relating to control drug release and achieving therapeutic efficacy. Recently, solid lipid nanoparticles (SLNs) were explored for their potential of topical delivery, possible skin compartments targeting and controlled release in the skin strata. The retention and accumulation of drug in skin is affected by composition of SLNs. Hence, the aim of this study was to develop FLZ nanoparticles consisted of various lipid cores in order to optimize the drug retention in skin. SLNs were prepared by solvent diffusion method and characterized for various in vitro and in vivo parameters. The results indicate that the SLNs composed of compritol 888 ATO (CA) have highest drug encapsulation efficiency (75.7 ± 4.94%) with lower particle size (178.9 ± 3.8 nm). The in vitro release and skin permeation data suggest that drug release followed sustained fashion over 24 h. The antifungal activity shows that SLNs made up of CA lipid could noticeably improve the dermal localization. In conclusion, CA lipid based SLNs are represents a promising carrier means for the topical treatment of skin fungal infection as an alternative to the systemic delivery of FLZ.

Loading Drug Delivery Research Laboratory collaborators
Loading Drug Delivery Research Laboratory collaborators